Skip Navigation Bar
National Intitutes of Health
This finding aids platform will be replaced in Fall 2022. Please explore the new platform Beta soft release by visiting https://archivesspace.nlm.nih.gov

Robert M. Chanock Papers 1933-2008 (bulk 1950-2008)
search terms in context | full text File Size: 260 K bytes | Add this to my bookbag

Box | Folder Title
 
Series 3: Lab Research, 1951-2008 [series]:
 
Lab Notebooks by researcher, 1958-2000 [subseries]:
21 1-2
Abinanti, Francis R., 1958-1964
21 3-19
Chanock, Robert M., 1958-2000
22 1-19
Chanock, Robert M. (cont'd), 1958-2000
23 1-19
Chanock, Robert M. (cont'd), 1958-2000
24 1-4
Chanock, Robert M. (cont'd), 1958-2000
24 5-8
Cook, M. Katherine, 1960-1975
24 9
Dans, Peter E., 1966-1967
24 10
Forsyth, Ben R., 1965-1966
24 11-18
Hoggan, M. David, 1972-1985
24 19
Johnson, Karl M., 1959-1962
25 1-3
Johnson, Karl M. (cont'd), 1959-1962
25 4-8
Kapikian, Albert Z., 1977-1981
25 9-10
Lewis, Marianne, 1972-1984
25 11-17
Mufson, Maurice A., 1962-1965
25 18-19
Rowe, Wallace P., 1958-1972
26 1-19
Rowe, Wallace P. (cont'd), 1958-1972
27 1-16
Rowe, Wallace P. (cont'd), 1958-1972
 
Lab Notebooks by Subject, 1954-1994 [subseries]:
27 17
CF Antigens, 1954-1975
27 18
Miscellaneous Virus, 1957
27 19
Neuraminidase, 1974-1993
28 1-8
Neuraminidase (cont'd), 1974-1993
28 9
Radioactive Materials, 1971-1974
28 10-16
Viral Reagents, 1962-1994
 
Research Data, 1950-2008 [subseries]:
28 17-19
Miscellaneous/Unidentified Studies, undated
29 1-7
Miscellaneous/Unidentified Studies (cont'd), 1950-2005
29 8
Japanese B encephalitis, 1951-1954
29 9
Lab studies on adenovirus, pneumonia or bronchiolites, 1952-1956
29 10
Avian Japanese B encephalitis, 1953-1955
29 11
Transplacental transmission polio virus, 1954-1955
29 12
Polio chick embryo, 1955
29 13
Yale - Monkey kidney trypsinization techniques Ph colon test, 1955-1956
29 14
Experiment 2. Assay of a high titer phage stock relation of plaque count to volume of phage suspension plated, 1956
29 15
Etiology of nonbacterial respiratory disease in infancy and childhood - NIH senior fellowship grant, 1956
29 16
Serology, 1956-1957
69 9
1 RSV collation, 1956-1957 [RESTRICTED PHI POLICY]
29 17
Croup, 1956-1959
29 18
Pap virus, 1958-1959
69 11
Mycoplasma - U.S. Naval Hospital, Beaufort, S.C. - patient summaries, 1959-1960 [RESTRICTED PHI POLICY]
29 19
Respiratory viruses and mycoplasmas clinical: Pap study - Parris Island, 1959-1961
29 20
#2 neutralization tests #19, 1959-1998
29 21
Immunization, 1961-1962
69 14-15
RS vaccine study, 1962-1975 [RESTRICTED PHI POLICY]
29 22
Contribution of adenoviruses to respiratory tract illness among children, 1963
29 23
Evaluation of WI-26 human diploid fibroblast cultures for isolation of adenovirus type 4, 1963
29 24-25
Lots of vaccine - Wyeth, 1963-1968
29 26-27
Mycoplasma, 1963-1992
29 28
Ludwig adeno capsule, 1964
29 29
Respiratory viruses and mycoplasmas clinical: adeno field trials - Parris Island, 1964-1965
30 1
Respiratory viruses and mycoplasmas clinical: m. pneumonia trials - Parris Island, 1965-1966
30 2
Respiratory viruses and mycoplasmas clinical: rs attenuated strain - 2, 1965-1970
69 18
Children's Hospital contract reports, 1965-1981 [RESTRICTED PHI POLICY]
30 3
Drug protocols - Wyeth, 1966
30 4
Respir. Viruses and mycoplasmas clinical: adeno field trials other, 1966-1967
69 17
RS vaccine study, 1967 [RESTRICTED PHI POLICY]
30 5
Experimental rubella vaccine lot 12-6/6A, 1967
30 6
Myxovirus recovery from respiratory tract illness - summary tables, 1967
30 7
Camargo, Ena - RSV - paraflu III plaque, 1967-1972
30 8-13
RS vaccine - Children's Hospital of D.C., 1967-1979
30 14-16
Production protocol - adenovirus vaccine, life, oral - type 7 - Wyeth, 1968-69
30 20
RS #3 challenge of para 1 new, November 1970
30 17
RS ts 1 mutant - Jessup, 30 December 1969
30 18
Clinical research protocols, 1969-1978
30 19
RS volunteer - wild type challenge of ts1 vaccinees, 13 February 1970
30 21
DBS-IND-294 Wyeth, adenovirus vaccine, type 7, live, oral - book 2, 1970-1972
30 22
Antibody response to m. pneumoniae vaccine, 1971
30 23
RSV clinical summary - Children's Hospital, 1971
30 24
Virus-associated immunopathology animal models and implications for human diseases, c.1972
30 25
RSV primates: to RS in children, c.1972-1973
69 23
Children's Hospital - nasal washings, 1972-1974 [RESTRICTED PHI POLICY]
30 26
Lab reports, 1973
30 27
Influenza A/1968 (H3N2) virus serum hemagglutination - inhibition antibody status of children before and after the Nov. 1972-Jan. 1973 epidemic of influenza A/1972 (H3N2) in Washington, D.C., 1973
30 28
Clinical observation of infants/children receiving RS-A2, ts-1 mutant, 1973
30 29
Mycoplasma vaccine trial (OSU-1) - Naval Medical Field Research Laboratory, 1974
30 30
Safety test protocol - A/Georgia/101/74 clone 1B, 1974
30 31
RS vaccine summaries - Children's Hospital, 1974-1975
31 1
RSV primates: bovine RSV in cotton rats, owl monkeys and chimps, 1974-1993
31 2
Swine influenza - Burroughs Wellcome Research Labs, 1975-1979
31 3
Camargo, Ena - RSV, 1975-1980
31 4
Huebner tumorigenicity TS-1-E (Morris), 1976
31 5
Status of two dose trials, 1976
31 6
Safety test - parainfluenza virus type 3, strain #22311 (lot F-367), 1976
31 7
RSV primates: genetic stability - stress tests RS, 1976-1989
31 8
Safety test of influ. A/VIC/3/75 (H3N2) x ts-1 [E], clone 81C1, recomb. virus (code CF/PP/1) - Flow Labs, 1977
31 9
Lot F-486 - RSV, strain A2, TS-1 NG-16 mutant, 1977-1979
31 10
RSV primates II, 1977-1991
31 11
Attenuated influenza vaccines, 1981
31 12
Nasal washings - Children's Hospital, 1981
31 13
RSV hr mutants in primates ts in primates: guinea pig kidney cell grown RSV - pass 18 chimps, 1981
31 14
RSV primates: cotton rat RS, 1981
31 15
RSV hr mutants in primates ts in primates: chick lung cell grown RSV passage 6 - chimps, 1982
31 16
RSV primates, 1982-1993
31 17
Research labs - Merck Sharp and Dohme, 1983-1991
31 18
SV40, 1983-2001
31 19-20
Production protocols - Wyeth, 1985
31 21
RSV hr mutants in primates ts in primates: primates studies RSV, 1986-1990
31 22
Immunization: flavi and alpha viruses, 1988
31 23
Prophylactic effect antibodies, 18 October 1988
31 24
MF59 Chiron, 1989-2006
31 25
RSV vaccine testing, 1989-2006
31 26
Fourth NIH rotavirus vaccine workshop, 5-6 November 1990
31 27
RSV ICN Krugman, 1991-1993
31 28
Flavivirus vaccine research - Walter Reed-NIAID, 1991-1994
31 29-30
RSV human fob monoclones, December 1991-February 1995
31 31
CA influenza virus - Wyeth, 1992-1993
31 32
RSV - Repligen, 1993
31 33
Fab 19 MARM, 1993-1995
31 34
RSV human FABS, 5 February 1995
31 35-36
AGMK cells, karyotype, tumor tests, patent, 1994-2000
32 1-3
Bovine RV (4x) clinical trial, 1997
32 4
U.S.-Russian collaboration final report, 1997
32 5-7
TBEV LGT, 1998-2000
32 8-9
TBEV II and West Nile, 2000
32 10
History of discovery and development of successful interventions, 2000
32 11
West Nile virus, 2000-2006
32 12
Periodic dengue, West Nile, TBEV meetings, 2001
32 13-14
Dengue vaccine part II, 2001-2007
33 13
Dengue virus and West Nile virus, 2008
32 15
Dengue virus vaccine development, 2002
33 1
TBEV and Langat II, 2002
33 2
Dengue virus vaccine data, 2003
33 3
Restoration of live adenoviruses vaccine in DOD, 2003-2005
33 4-6
Negative SV40, 2004
33 7-8
Positive SV40, 2004
33 9
Dengue virus vaccine development, 2004
33 10
Clinical WN/Den4 serology immunogenicity - clinical Lat/Den4 serology immunogenicity, 2005
33 11
Dengue candidates, August 2006
33 12
Den langat, 2006
 
LID Lab Research Reports, 1960-2004 [subseries]:
33 14-27
Clinical research projects, 1960-1982
33 28
NIAID ad hoc contract review, 1973
33 29
Experimental immunoprophylaxis against respiratory syncytial virus infections in primates, undated
33 30
Experimental infection of primates with respiratory syncytial virus, undated
33 31
Histological and virological study of the neurovirulence in rhesus monkeys of a langat/dengue 4 chimeric virus and its parental strains langat virus and dengue type 4 virus, undated
33 32
Virological analyses of recombinant, live, attenuated respiratory syncytial virus subgroup A strain rA2cp248/404/1030ΔSH in healthy unscreened 4-12 weeks old infants, undated
33 33
RNA tumor viruses as etiologic agents of solid tumors as well as leukemia - NIAID/NCI collaborative research, 1968
33 34
Determination of the effect of an inducer of interferon (IN-CN) administered to upper respiratory tract on experimentally induced respiratory virus infections, 1969
33 35
Safety of cold adapted respiratory syncytial virus vaccine in infants 6-7 months of age, 1969
33 36
Serum complement in acute bronchiolitis, 1969
33 37
Pediatric adenovirus vaccine evaluations, 1971
33 38
Fort Detrick reports, 1972-1977
34 1
Chanock scientific studies, 1973-1992
34 2
Transferring viruses to NIAID, 1997-1998
34 3
Development of a rotavirus vaccine for the prevention of severe rotavirus diarrhea of infants and young children - LID Epidemiology section, c.2000
34 4-5
Development of new approaches for vaccines against the tick-borne encephalitis virus complex - Molecular Viral Biology section, 2000-2001
34 6
Phase I study of Ad4-ΔE3-HIVenv and Ad4-ΔE3-HIV/gag/pro recombinant vaccines in HIV-negative volunteers, 2001
34 7
Projected schedule for WNV/DEN4 chimera studies, 2001
34 8
New molecular approaches to develop live attenuated vaccines against the tick-borne encephalitis complex and the West Nile encephalitis virus, 2003
34 9
The development of vaccines for parainfluenza virus types 1, 2, and 3 - Respiratory Viruses section, 2004
34 10
In vitro models of paramyxovirus infection, 2004
34 11
New molecular approaches to develop live attenuated vaccines against tick-borne encephalitis virus complex and the West Nile and St. Louis encephalitis viruses - Respiratory Viruses section, 2004
34 12
NIAID 69-A - Study of non-bacterial respiratory disease A) children, 1966-1969
34 13
NIAID 69-B - Non-bacterial respiratory disease in military recruits - epidemiology and experimental immunoprophylaxis, 1966
34 14
NIAID 69-C - The etiology of acute respiratory disease in civilian adults, 1965
34 15
NIAID 69-D - Collaborative studies of biophysical properties of respiratory viruses which are important to the development of vaccines, 1966
34 16
NIAID 70-A - Laboratory studies of newly r4ecognized viruses associated with respiratory illness, 1966
34 17
NIAID 70-B - Characterization of newly discovered rhinovirus serotypes of human origin, 1966
34 18
NIAID 70-C - Basic studies on mycoplasma, 1966
34 19
NIAID 70-C.1 - Serology and seroepidemiology of mycoplasmas (pleuropneumonia-like organisms - PPLO), 1966
34 20
NIAID 70-D - Laboratory studies of viral hepatitis agents, 1966
34 21
NIAID 70-E - Biological and biophysical studies of rhinoviruses, 1966-1969
34 22
NIAID 72-B - Study of respiratory viruses and mycoplasmas in human volunteers, 1969
 
Investigational New Drugs (IND), 1963-2001 [subseries]:
34 23
Unnumbered - Attenuated quadrivalent human-bovine (UK) rotavirus reassortant vaccine - original submission, 1995
34 24
Unnumbered - Wild-type and attenuated respiratory syncytial viruses; subgroup B, 1993
34 25
IND #24 - Parainfluenza type 3 vaccine - suppl. 1-4, 1963-1967
34 26-31
IND #71 - Live adenovirus type 4 enteric vaccine - suppl. 31-50, 1967-1972
34 32-35
IND #93 - Parainfluenza virus vaccines (types 1, 2, and 3) - suppl. 1-24, 1964-1973
35 1-2
IND #93 - Parainfluenza virus vaccines (types 1, 2, and 3) - suppl. 1-24 (cont'd), 1964-1973
35 3
IND #385 - Monovalent adenovirus type 2 soluble antigen vaccine, aqueous or alum absorbed - suppl. 1, 4-6, 1969-1971
35 4
IND #386 - Live, attenuated rubella virus vaccine strain HPV-79-RK 7, lot 31764 - suppl. 2-3, 1969
35 5
IND #401 - Meningococcal group C vaccine - suppl. 1-36, 1969-1973
35 6-7
IND #419 - Complexed polyinosinic and polycytidylic acids - suppl. 1-13, 1969-1970
35 8-9
IND #421 - Parainfluenza 3 challenge pool (attenuated?) - suppl. 1-23, 1969-1973
35 10
IND #437 - Pneumococcal polysaccharide vaccines, 1970-1972
35 11
IND #450 - Vaccinia virus vaccine -suppl. 7, 1971
35 12
IND #582 - H. Influenzae type b PRP vaccine - suppl. 10, 188, 1972-1987
35 13-20
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399, 1972-1995
36 1-17
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
37 1-18
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
38 1-18
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
39 1-18
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
40 1-18
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
41 1-3
IND #601 - Live, attenuated influenza A virus (H3N2) vaccines (ts mutants and recombinants of them) - suppl. 1-399 (cont'd), 1972-1995
41 4-5
IND #734 - TS mutants of mycoplasma pneumoniae - suppl. 1-1C (inactive), 1974-1977
41 6
IND #735 - Inactivated monovalent influenza B virus vaccine, 1973
41 7-8
IND #825 - Inactivated influenza A virus vaccines subunit - suppl. 1-30, 1974-1980
41 9
IND #839 - Poly I; poly C: poly-l-lysine - suppl. 1, 1974
41 10
IND #1044 - Live parainfluenza virus vaccines types 1, 2, and 3, placebo - suppl. 1-8 (inactive), 1975-1978
41 11-19
IND #1115 - Inactivated influenza A virus vaccines QA/NJ/1976 - suppl. 1-51, 1976-1980
42 1-6
IND #1115 - Inactivated influenza A virus vaccines QA/NJ/1976 - suppl. 1-51 (cont'd), 1976-1980
42 7
IND #1287 - Adenovirus subunit vaccines - suppl. 1-11, 1978-1982
42 8-17
IND #1298 - Inactivated influenza A virus vaccines (H1N1) - suppl. 1-118, 1978-1990
43 1-17
IND #1298 - Inactivated influenza A virus vaccines (H1N1) - suppl. 1-118 (cont'd), 1978-1990
43 18
IND #1384 - Live attenuated respiratory syncytial virus vaccine - suppl. 1-29, 37, 1979-1993
44 1-5
IND #1384 - Live attenuated respiratory syncytial virus vaccine - suppl. 1-29, 37 (cont'd), 1979-1993
44 6
IND #1462 - Varicella virus vaccine - suppl. 123, 1987
44 7-20
IND #1530 - Live human rotavirus (Wa strain, subgroup 2 [formerly type 2]) vaccine candidate - suppl. 1-125, 139, 1980-1998
45 1-15
IND #1530 - Live human rotavirus (Wa strain, subgroup 2 [formerly type 2]) vaccine candidate - suppl. 1-125, 139 (cont'd), 1980-1998
45 16
IND #1808 - E. coli CFA/II pili vaccine oral - suppl. 4, 1985
45 17
IND #1914 - Interferons - suppl. 9-10, 1985
45 18
IND #2000 - Vi capsular antigen - suppl. 4, 1985
45 19-21
IND #2843 - Live attenuated parainfluenza virus vaccines - supple 1-63, 1988-1995
46 1-7
IND #2843 - Live attenuated parainfluenza virus vaccines - supple 1-63 (cont'd), 1988-1995
46 8-10
IND #2858 - Bovine parainfluenza virus type 3 - suppl. 1-30, 1988-1994
46 11-14
IND #4006 - Rhesus rotavirus vaccines, live, (tetravalent, serotypes 1, 2, 3, and 4) oral - suppl. 1-25, 1988-1998
46 15-19
IND #4942 - Wild-type and attenuated respiratory syncytial viruses; subgroup A - suppl. 1-58, 1993-2000
47 1-5
IND #4942 - Wild-type and attenuated respiratory syncytial viruses; subgroup A - suppl. 1-58 (cont'd), 1993-2000
47 6-9
IND #4981 - Respiratory syncytial virus subgroup B (strain 14617, vero 1 cells) wild type and attenuated live vaccines - suppl. 1-33, 1993-2000
47 10
IND #7762 - Respiratory syncytial virus, live, attenuated vaccine and purified fusion protein with alum - suppl. 1-6, 8-9, 1998-2001
 
Research Contracts, 1952-2001 [subseries]:
 
Proposals, 1955-2001 [subseries]:
47 11
Unidentified, undated
47 12
Etiology of viral diarrheas - part III, undated
47 13
To obtain a recombinant form of type 1 poliomyelitis virus capable of multiplication in the embryonated egg, 1955
47 14
Assess antigenicity and effectiveness in infants and children of vaccines against newly discovered viruses responsible for respiratory tract illness. . ., c.1964
47 15
The isolation of viruses and viral subunits, 1964
47 16
Respiratory syncytial virus vaccine concentrated 100-fold from monkey kidney tissue cultures, c.1965
47 17
Studies on adenovirus vaccines, c.1965
47 18
Biochemical and immunologic investigations of neisseria meningitidis, 1965
47 19
Development of prototype, inactivated vaccines for respiratory syncytial and parainfluenza viruses and for mycoplasma pneumoniae, 1965
47 20
To assess the antigenicity and effectiveness in infants and children of vaccines against newly discovered viruses responsible for respiratory tract illness. . ., 1965
47 21
Concentration of human hepatitis virus (supplement to NIAID Support of Man program), 1966
47 22
Proposed vaccine studies, Kansas City, 1966
47 23
Respiratory virus vaccines, 1967
47 24
Tests in infants and children for antigenicity and effectiveness of inactivated vaccines, 1967
47 25
X-ray crystal structure of adenovirus coat protein, 1969
47 26
Respiratory viral vaccines and pathogenesis of respiratory viral disease in infants and children, 1971
47 27
Studies on hemophilus influenzae b vaccine, c.1972
47 28
Specific cell-mediated immunity to respiratory syncytial virus in infants and children following natural infection or immunization, 1974
47 29
Hybridization of highly radioactive adenovirus DNA strands with cancer DNA to detect viral DNA copies in human cancer cells, 1975
47 30
Evaluation of skin test reactivity during wild type and temperature sensitive influenza virus infection, 1975
47 31
Protective efficacy of langat virus vaccines in mice - animal study proposal, 1997
47 32
Evaluation of protective efficacy of dengue vaccines in mice - animal study proposal, 1999
47 33
Evaluation of chimeric TBEV/DEN4 virus vaccines in mice, 2001
47 34
Immunogenicity and protective efficacy of langat virus vaccines in mice, 2001
 
Reports, 1952-1998 [subseries]:
47 35-39
National Foundation for Infantile Paralysis - Children's Hospital, Cincinnati, 1952-1956
47 40
Vaccine development program commitments, 1965
47 41
Respiratory vaccine development, 1966
47 42
Induced upper respiratory tract infection of man with living adenovirus vaccine type 4, study #1, Lorton Reformatory, 1967
47 43
NIAID Molecular Anatomy Program, 1967
47 44
Evaluation of a live type 4 adenovirus vaccine, 1967-1968
47 45
Acute infectious nonbacterial gastroenteritis, 1973
47 46
103, 1169, 943 - Tissue culture and serology oncogenicity studies, RSV studies, 1964-1965
47 47
6-61-03-032 - Studies on virus and rickettsial diseases, 1953
47 48
263-81-C-0295 - Providing lung tissue, blood samples and nasal secretions, 1981
47 49
263-82-C-0037 - Providing lung tissue, blood samples and nasal secretions, 1981
47 50
3A014501B71Q - Communicable diseases - immunology, c.1966
47 51
DA-49-007-MD-950 - Comparison of aqueous and adjuvant adenovirus vaccines, 1963
47 52
DA-49-193-MD-2131 - Purification, characterization and synthesis of components of adenovirus, 1965
47 53
DA-49-193-MD-2189 - Studies on the etiology and epidemiology of acute respiratory infections, 1965
47 54
DA-49-193-MD-2495 - Genetic relationships among human and animal strains of influenza virus, 1967
47 55
DA-49-193-MD-2795 - Recombination and transmission studies with influenza virus, 1971
47 56
DADA-17-70-C-0121 - Purification, characterization, and synthesis of components of adenovirus, 1971
47 57
M4305.01-1011 BFG6; M4305.01-1012 BFG6 - Epidemiology and prevention fo acute respiratory disease in navy recruits, 1972
48 1
NIH-69-91 - Laboratory and antigenic studies of RSV; evaluation of respiratory syncytial, mimingococccal, and pneumococcal polysaccharide vaccines, 1970
48 2
NIH-69-2072 - Research and development of adenovirus vaccines and parainfluenza virus vaccines, 1970
48 3
NIH-69-2109 - To develop improved polyvalent adenovirus vaccine to provide a base for others against viral agents in respiratory illness, 1969
48 4
NIH-71-2091 - The assessment of antigenicity and effectiveness of respiratory disease vaccines, 1971
48 5-6
NIH-71-2196 - Respiratory viral vaccines and pathogenesis of respiratory viral disease in infants and children, 1971, 1973
48 7
N01-AI-01528 - New viruses in relation to clinical diseases, 1968-1972
48 8-9
N01-AI-02638 - Operation of a virus vaccine production laboratory, 1980-1981, 1983-1987
48 10
N01-AI-02653 - Center for the clinical testing of bacterial vaccines, respiratory virus vaccines and antivirals, 1981
48 11-13
N01-AI-05057 - University of Puerto Rico, 1991-1992
48 14-15
N01-AI-05067 - Care and housing of AIDS research animals, 1990-1991
48 16
N01-AI-17757 - Children's Hospital, 1980-1981
48 17-19
N01-AI-22503 - Clinical evaluation of respiratory viral and bacterial vaccines in children and adults, 1972-1989
48 20
N01-AI-22504 - Development of attenuated mutants of respiratory syncytial virus and parainfluenza viruses as potential vaccine strains, 1974
48 21
N01-AI-22508 - Clinical evaluation of influenza virus vaccines, 1974
48 22
N01-AI-35154 - Protocol relating to the passage, history, production, safety testing and characterization of an experimental live virus vaccine pool of influenza A/Beijing/352/89 (H3N2) . . ., 1993-1994
49 1-2
N01-AI-32521 - Operation of a virus laboratory in support of LID, 1974-1990
49 3-4
N01-AI-42510 - Preparation of isolated hemagglutinin, neuraminidase, matrix, and nucleoprotein subunits of influenza viruses and assay of their immunogenicity, 1978
49 5
N01-AI-42528 - Influenza research center, 1979
49 6
N01-AI-52565, 1985-1987
49 7-8
N01-AI-72535 - Establishment of an infectious enteric disease study, 1978-1979
49 9-10
N01-AI-82681 - Operation of an experimental virus vaccine production laboratory, 1988-1989
49 11
N01-AO-52703 - Care and housing of AIDS research animals, 1997-1998
49 12
N01-AO-52706 - Facility for non-human primates utilized in infectious disease research, 1998
49 13
PH-40-30-64 - Development of a technique for virus and viral subunit isolation from large volumes of tissue culture, 1966
49 14
PH-43-62-80 - Production of enterovirus antisera, 1965
49 15
PH-43-62-127 - Preparation of immune serum to enteroviruses, 1965
49 16
PH-43-62-129 - Standardization of picornavirus immune sera, 1965
49 17-26
PH-43-62-473; PH-43-66-917 - Antigenicity and protection studies on inactivated 100X concentrated RSV vaccine and inactivated 100X concentrated parainfluenza 1 virus vaccine, 1962-1970
49 27-29
PH-43-62-477 - Respiratory virus vaccine evaluation and surveillance, 1966-1968
49 30-32
PH-43-62-487 - Research and development of rhinovirus, mycoplasma pneumoniae, and RS vaccines, 1966-1968
49 33
PH-43-62-839 - Preparation of mycoplasma antigene and antisera, 1965
49 34-35
PH-43-63-75 - Respiratory disease surveillance and vaccine studies in military dependent children, 1968, 1970
49 36-38
PH-43-63-76 - Viral respiratory disease and immune response in the aged and in a pediatric population, 1966-1968
50 1-4
PH-43-63-79 - Research and development of adenovirus vaccines and parainfluenza virus vaccines and adaptation of RSV to embryonated eggs of several avian species, 1964-1966
50 5-6
PH-43-63-80 - To develop improved polyvalent adenovirus vaccine to provide a base for others against viral agents in respiratory illnesses, 1965, 1967
50 7
PH-43-63-81 - Development, growth and characterization of virus induced tumor cells, 1967
50 8
PH-43-63-90 - Upper respiratory virus, 1965
50 9
PH-43-63-103 - Operation of a serology and tissue culture developmental laboratory, 1966
50 10-11
PH-43-63-562 - Prevention of viral respiratory infections, 1964, 1968
50 12
PH-43-63-563 - Vaccine studies in a children's center, 1968
50 13
PH-43-63-564 - Research on attenuation of rhinoviruses and methods for measuring antibody response to rhinovirus infection, 1967
50 14-16
PH-43-63-582 - Respiratory disease vaccine, 1962-1967
50 17-18
PH-43-63-1128 - Surveillance of respiratory infections in an industrial population, 1966, 1968
50 19-20
PH-43-63-1141 - Surveillance of viral respiratory diseases and vaccine evaluation in a pediatric population, 1967-1968
50 21
PH-43-63-1163 - Studies on the response of primates to respiratory syncytial virus, 1964
50 22
PH-43-63-1174 - World Health Organization Reference Centre for Enteroviruses, 1965
50 23
PH-43-63-1177 - Reference seeds for echo and coxsackieviruses, 1965
50 24
PH-43-64-529 - Preparation and development of viral reagents, 1965
50 25-27
PH-43-64-928 - Molecular structure of oncogenic and non-oncogenic adenoviruses and the mechanism of viral carcinogenesis, 1966, 1968, 1972
50 28-29
PH-43-64-943 - Developmental study relating to the preparation of a respiratory syncytial virus vaccine, 1966-1967
50 30-32
PH-43-64-1169 - Oncogenicity testing of candidate viral respiratory vaccine strains and tumor reagent programs, 1965-1967
50 33-34
PH-43-65-562 - Rhinovirus reference laboratory, 1966-1967
50 35-36
PH-43-65-563 - Studies of RSV vaccines, 1966-1967
50 37
PH-43-65-1004 - Characterization and propagation of live rubella vaccine candidate strains and production reagents, 1968
50 38-40
PH-43-65-1031 - Study of vaccines for immunization against viral respiratory infections, 1966-1968
50 41
PH-43-66-63 - The testing of experimental respiratory agents and vaccines in volunteers, 1966
50 42-43
PH-43-66-93 - Rubella vaccine development, 1967-1968
50 44
PH-43-66-99 - Research on the feasibility of preparing inactivated and/or attenuated rubella virus vaccines, 1967
50 45
PH-43-66-459 - Research and development of attenuated and inactivated rubella vaccines, 1968
50 46-47
PH-43-66-461 - Research and development of an inactivated rubella virus vaccine, 1967-1968
50 48
PH-43-66-462 - Epidemiology of respiratory disease in total natural community and evaluation of immunizing agents, 1966
50 49
PH-43-66-464 - Studies on the detection of rubella virus and its immunogenicity for animals and man, 1966-1968
50 50
PH-43-66-565 - Development of a live vaccine for human influenza, 1966
50 51-52
PH-43-66-917 - The role of infection in precipitating sudden deaths in infants, 1969
50 53-54
PH-43-66-951 - Maintenance of a marmoset colony under strict isolation conditions, 1967-1968
50 55
PH-43-66-970 - Operation of a tissue culture developmental laboratory, 1967
50 56
PH-43-66-971 - Provide for the operation of a serology laboratory, 1967
50 57-58
PH-43-67-48 - Longitudinal studies of acute respiratory diseases in children, 1968, 1970
50 59-60
PH-43-67-75 - The testing of rubella virus vaccines in human volunteers, 1967-1968
50 61
PH-43-67-76 - Identification, characterization, purification and concentration of the antigens of respiratory syncytial virus, 1968
50 62
PH-43-67-77 - Biologic and antigenic studies with rubella virus, 1968
50 63
PH-43-67-78 - The influence of cultural conditions and concentration procedures on the antigenicity of mycoplasma pneumoniae vaccines, 1968
50 64-65
PH-43-67-79 - Study of the antigenicity and immunogenicity of mycoplasma pneumoniae vaccines, 1967
50 66
PH-43-67-80 - Studies of rubella vaccine efficacy, 1967
50 67
PH-43-67-91 - Research and development of respiratory disease vaccines, 1967-1968
50 68
PH-43-67-681 - Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines, 1973
50 69
PH-43-67-692 - Search for virus-specific genetic material in human cancers and studies on the mechanism of viral carcinogenesis, 1969
50 70-71
PH-43-67-745 - Studies of local antibody in respiratory viral immunity, 1967, 1969
50 72
PH-43-68-81 - Operation of a rubella virus service laboratory, 1968
50 73
PH-43-68-83 - Primary immunization of infants with group A streptococcal M protein, 1968
50 74
PH-43-68-692 - Research and development of rhinovirus and mycoplasma pneumoniae vaccines, 1968
51 1-4
PH-43-68-1309 - Development of chemically induced conditional-lethal temperature-sensitive (ts) mutants of RS and parainfluenza viruses, 1968-1975
51 5-6
PH-43-68-1316 - To develop improved polyvalent adenovirus vaccine to provide a base for others against viral agents in respiratory illness, 1968-1969
51 7
Z01-AI-00024 - Laboratory studies of myxoviruses, paramyxoviruses and respiratory syncytial virus, 1977
51 8
Z01-AI-00175 - Laboratory studies of paramyxoviruses and respiratory snycytial virus, 1978-1981
 
Cooperative Research and Development Agreements (CRADA), 1972-2003 [subseries]:
51 9
License agreements, 1988-1996
51 10-11
Chiron, 1988-2003
51 12-15
Intracel, 1995-1997
51 16-21
Lederle, 1992-2000
52 1-10
Lederle (cont'd), 1992-2000
52 11
MedImmune, 2002
52 12
Praxis, 1987-1988
52 13
Upjohn, 1988
52 14-27
Wyeth, 1972-2001
53 1-5
Wyeth (cont'd), 1972-2001